The Recall Desk
SevereFDA (Drugs)·D-0226-2017·Announced 2016-12-28

Amgen Recalls Kyprolis Vials Due to Potential Glass Cracks

Amgen is recalling 11,434 vials of Kyprolis (carfilzomib) injection because potential cracks in the glass vials may compromise sterility.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls involving significant injury/property-damage reports or structural defects (glass cracks compromising sterility) are rated Severe (4).

Plain-English summary

Amgen, Inc. is recalling 11,434 vials of Kyprolis (carfilzomib) for injection, 30 mg per vial. The recall is due to a lack of assurance of sterility caused by potential cracks in the glass vials.

The affected product is identified by Lot #1071559 and #1071629, with an expiration date of 05/18. The product was distributed in the United States and Puerto Rico. No foreign distribution occurred.

Healthcare providers and patients should stop using the affected vials and contact Amgen or their healthcare provider for further instructions.

The recalled product

Product
KYPROLIS (CARFILZOMIB)
Brand
KYPROLIS
Manufacturer
Amgen, Inc.
Affected units
11,434

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (3)

  • Lot #1071559
  • 1071629
  • Exp. 05/18

Distribution

Distributed in 1 state: